Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q1 FY24 results · Apr–Jun 2023
Supriya Lifescience reported revenue from operations of ₹132.02 crore (up 30.3% from Q1 FY23) and net profit of ₹28.51 crore (up 12.9% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a standalone basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 132.02 | 101.36 | +30.3% | 142.27 | −7.2% |
| Other income | 2.92 | 2.36 | +23.8% | 1.96 | +48.6% |
| Total income | 134.94 | 103.71 | +30.1% | 144.23 | −6.4% |
| Profit before tax | 42.64 | 30.14 | +41.5% | 53.29 | −20.0% |
| Net profit for the period | 28.51 | 25.25 | +12.9% | 38.23 | −25.4% |
| EPS, basic (₹) | 3.54 | 3.14 | +12.7% | 4.75 | −25.5% |
| Net margin (%) | 21.6 | 24.9 | 26.9 |
Standalone
- Filed with BSE
- 04 Aug 2023, 12:12 IST
- Board meeting
- 03 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE